NASDAQ

Loxo Oncology Reports First Quarter 2018 Financial Results

- LOXO-292 Phase 1 Oral Presentation Upcoming at 2018 ASCO Annual Meeting - - ...

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that EMA has given 60 days response ...

US FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD

Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update ...

US FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD

Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update ...

US FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD

Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update ...

US FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD

Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update ...